Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02

Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results

Genentech, a member of the Roche, announced positive results from the Phase III IMpassion130 study of Tecentriq plus chemotherapy - Abraxane - for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer. The Tecentriq and chemotherapy combination significantly reduced the risk of disease worsening or death compared with chemotherapy alone in all randomized patients and the PD-L1-positive population, a subgroup determined by PD-L1 biomarker testing. At this interim analysis, statistical significance was not met for overall survival in the ITT population, but showed a clinically meaningful 9.5-month OS improvement in the PD-L1-positive population. Due to the hierarchical statistical design, results in the PD-L1-positive population were not formally tested. Follow-up will continue until the next planned analysis. Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

CLX

Clorox

$158.67

3.36 (2.16%)

15:27
02/21/19
02/21
15:27
02/21/19
15:27
Earnings
Clorox sees long-term total company annual growth of 3%-5% »

Clorox sees long-term…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 04

    Mar

  • 28

    May

AAOI

Applied Optoelectronics

$14.45

-0.17 (-1.16%)

15:19
02/21/19
02/21
15:19
02/21/19
15:19
Options
Applied Optoelectronics options imply 25.6% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
02/21/19
02/21
15:17
02/21/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
02/21/19
02/21
15:16
02/21/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IART

Integra LifeSciences

$55.50

3.58 (6.90%)

15:10
02/21/19
02/21
15:10
02/21/19
15:10
Recommendations
Integra LifeSciences analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.43

-0.07 (-0.08%)

15:10
02/21/19
02/21
15:10
02/21/19
15:10
Options
Far downside ratio spread opened in High Yield Bond Fund »

Far downside ratio spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWDP

DowDuPont

$55.19

-1.06 (-1.88%)

15:06
02/21/19
02/21
15:06
02/21/19
15:06
Hot Stocks
Corteva Agriscience announces U.S. launch of Enlist E3 soybeans »

Corteva Agriscience, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 27

    Feb

  • 04

    Mar

  • 04

    Mar

  • 13

    Mar

  • 28

    May

EXAS

Exact Sciences

$82.81

-0.79 (-0.94%)

15:04
02/21/19
02/21
15:04
02/21/19
15:04
Options
EXACT Sciences options imply 15.0% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 22

    Feb

  • 18

    May

GE

General Electric

$10.05

-0.055 (-0.54%)

15:00
02/21/19
02/21
15:00
02/21/19
15:00
Options
100K GE Mar 8th 9 puts bought for 5c with shares flat at $10.10 »

100K GE Mar 8th 9 puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$43.81

-1.35 (-2.99%)

14:59
02/21/19
02/21
14:59
02/21/19
14:59
Periodicals
Anadarko says 4 injured in attack at Mozambique LNG project, Bloomberg reports »

Anadarko Petroleum said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Apr

  • 22

    May

ALB

Albemarle

$88.17

5.35 (6.46%)

14:54
02/21/19
02/21
14:54
02/21/19
14:54
Recommendations
Albemarle analyst commentary  »

Albemarle price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 27

    Feb

  • 27

    Feb

PBR

Petrobras

$16.70

-0.01 (-0.06%)

14:53
02/21/19
02/21
14:53
02/21/19
14:53
Periodicals
Brazil minister says Petrobras TOR auction may occur in late 2019, Reuters says »

Brazil's Energy and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

TI

Telecom Italia

$5.92

-0.12 (-1.99%)

14:51
02/21/19
02/21
14:51
02/21/19
14:51
Hot Stocks
Telecom Italia sees organic group EBITDA to decrease low single digit in 2019 »

TIM's Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:50
02/21/19
02/21
14:50
02/21/19
14:50
Hot Stocks
Breaking Hot Stocks news story on Tim Participacoes »

TIM Participacoes trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROKU

Roku

$51.60

-2.03 (-3.79%)

14:49
02/21/19
02/21
14:49
02/21/19
14:49
Options
Roku options imply 18.8% move in share price post-earnings, below median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

, QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

14:47
02/21/19
02/21
14:47
02/21/19
14:47
Conference/Events
Quad/Graphics to host special shareholder meeting »

Special Shareholder…

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

QUAD

Quad/Graphics

$15.85

-0.42 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

FB

Facebook

$160.21

-2.4 (-1.48%)

14:46
02/21/19
02/21
14:46
02/21/19
14:46
Periodicals
Kids advocacy groups urge FTC to probe Facebook over game purchases, Adweek says »

Childrens' advocacy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 03

    Mar

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

, LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

14:41
02/21/19
02/21
14:41
02/21/19
14:41
Conference/Events
LSC Communications to host special shareholder meeting »

Special Shareholder…

QUAD

Quad/Graphics

$15.80

-0.47 (-2.89%)

LKSD

LSC Communications

$9.23

-0.17 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

GIL

Gildan Activewear

$34.04

-0.13 (-0.38%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Downgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TSU

Tim Participacoes

$16.30

0.03 (0.18%)

14:37
02/21/19
02/21
14:37
02/21/19
14:37
Earnings
Tim Participacoes releases guidance for 2019-2021 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRP

Ctrip

$32.55

-1.24 (-3.67%)

14:35
02/21/19
02/21
14:35
02/21/19
14:35
Options
Ctrip.com put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Mar

  • 04

    Mar

  • 20

    Mar

NAII

Natural Alternatives International

$11.15

(0.00%)

14:34
02/21/19
02/21
14:34
02/21/19
14:34
Hot Stocks
Natural Alternatives International hires David Brook for sports nutrition unit »

Natural Alternatives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTDOY

Nintendo

$0.00

(0.00%)

14:24
02/21/19
02/21
14:24
02/21/19
14:24
Hot Stocks
Nintendo of America president, COO Reggie Fils-Aime to retire »

Nintendo announced that,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$14.83

-0.21 (-1.40%)

14:23
02/21/19
02/21
14:23
02/21/19
14:23
Hot Stocks
Fiat Chrysler to propose EUR0.65 per share dividend »

Fiat Chrysler Automobiles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWZ

MSCI Brazil Index

$43.43

-0.32 (-0.73%)

14:20
02/21/19
02/21
14:20
02/21/19
14:20
Options
20K iShares Brazil Fund Mar 44 - 46 call spreads sold at 60c »

20K iShares Brazil Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.